Remedy telegram

from Wikipedia, the free encyclopedia
drug telegram

description Trade journal for doctors and pharmacists
Area of ​​Expertise Pharmacology, pharmacy, medicine
language German
publishing company ATI Pharmaceutical Information Berlin GmbH
First edition 1970
Frequency of publication per month
Editor-in-chief Wolfgang Becker-Brüser
editor ATI Pharmaceutical Information Berlin GmbH
Web link arznei-telegramm.de
ISSN (print) 0066-8192

The arznei-telegram (abbreviation: at) is a German medical journal . With the exception of readers' inquiries, the exclusively editorial contributions are published in print and electronically. The magazine, which can only be obtained by subscription and is financed solely through sales, appears monthly and is ad-free. According to its own account, it is independent of the pharmaceutical industry and other interest groups and offers information on rational therapy . The publisher is ATI Medicines Information Berlin GmbH in Berlin . The journal is a member of the International Society of Drug Bulletins .

In 2005 arznei-telegramm founded the medical lay magazine Gute Pillen - Bad Pillen together with the authors and editors of Der Arzneimittelbrief and Pharma-Brief . Since 2008 he has also been co-editor in the practice .

content

The aim of the arznei-telegram is to inform doctors, pharmacists and members of other health professions about the benefits and risks of drugs and other therapeutic methods, e.g. B. of medical devices. The content of the mostly eight-page editions of the journal is characterized by articles that evaluate current therapies on the basis of reliable studies and classify them in the context of existing therapy options. In addition, the arznei-telegramm publishes letters to the editor and occasionally original articles .

The at articles are not identified by name. They are critically checked by all members of the editorial team and external consultants named in the imprint. The content of the at is borne by all members of the editorial team.

In the spotlight

This section usually contains editorial articles on a current topic. This can be a recently published clinical study, a freshly published therapy recommendation or a current health policy development. The articles often address the possible influence of the pharmaceutical industry as well as the non- publication of study data ( publication bias ) and distorted presentations of study results, which could pave the way for therapy decisions for inadequately tested or for risky drugs.

New on the market

In this section, the arznei-telegram presents new drugs, which it evaluates based on published clinical studies and other material from manufacturers and regulatory authorities. New drugs and drugs that have not been on the market for longer than five years or are under official surveillance are marked with a black triangle in the journal. The assessment is mostly critical. Also pharmacoeconomic aspects play a role in the evaluation. New therapeutics often do not receive any therapy recommendations from the editors, as they are mostly inadequately tested and there are often no suitable comparative studies with proven standard therapeutics. The resulting predominantly negative evaluation of new therapeutics has been criticized by the pharmaceutical industry and specialist circles.

In a nutshell

In the “In a nutshell” section, the editorial team provides brief information on pharmacological developments and classifies them critically in the current state of knowledge.

Readers ask and comment

In the “Readers Ask and Comment” section, subscribers have the opportunity to comment on an article or to ask questions about therapeutics. Author of letters to the editor are obliged to state their identity and to disclose any conflicts of interest. Questions are answered by the editorial team.

Network up to date

Under this heading, the arznei-telegram reports on new and, in the opinion of the editors, too little-known undesirable effects or interactions that the at has recognized in the network of mutual information. This is a recording system founded in 1986 with which the editorial team of the journal records and evaluates reports from specialist circles - sometimes also from patients. "Netzwerk aktuell" texts provide case descriptions of serious events that are temporally related to a drug application. A critical classification of the respective drug usually takes place afterwards.

Original article

The arznei-telegram very rarely publishes original articles. According to the magazine, special consideration is given to articles that could not be published elsewhere for political reasons. In contrast to the authors of the editorial contributions, the authors of these articles are named in detail and disclose possible conflicts of interest .

editorial staff

editor

The arznei-telegram has been published since 1970. It was created in 1969 from leaflets from a group of young doctors and pharmacists called the Independent Working Group on Medicinal Policy Berlin (UAAB) . The current publisher, ATI Medicines Information Berlin GmbH, also provides the atd medicinal product database against a license. In this, the drugs are presented and evaluated systematically, independently and without advertising. The database is the digital continuation of the drug course book .

Web links

  • arznei-telegramm.de. ATI Medicines Information Berlin GmbH, accessed on August 17, 2020 .
  • Good pills - bad pills. Non-profit society for independent health information mbH, joint project of: The drug letter, arznei-telegramm, pharmaceutical letter and drug regulation in practice (AVP), accessed on August 7, 2010 : "Consumer magazine"

Individual evidence

  1. ↑ a b c arznei-telegram internal - who we are and how we work. In: arznei-telegramm.de. ATI Medicines Information Berlin GmbH, November 1, 2019, accessed on August 17, 2020 .
  2. ↑ Good Pills - Bad Pills Imprint , accessed on May 18, 2010.
  3. ↑ Who we are and how we work. In: www.arznei-telegramm.de. Retrieved August 20, 2020 .